Stockscreener 앱 받기
20.73
3.98%
-0.86
전일 마감가:
$21.59
열려 있는:
$22
하루 거래량:
809.55K
Relative Volume:
0.91
시가총액:
$2.98B
수익:
$340.81M
순이익/손실:
$-419.65M
주가수익비율:
-7.2737
EPS:
-2.85
순현금흐름:
$-402.10M
1주 성능:
-2.99%
1개월 성능:
-10.03%
6개월 성능:
-17.08%
1년 성능:
+25.41%
1일 변동 폭
$20.68
$22.05
1주일 범위
$20.68
$22.81
52주 변동 폭
$14.56
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
명칭
Denali Therapeutics Inc
전화
(650) 866-8548
주소
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
DNLI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
20.73 | 2.98B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2025-01-07 | 개시 | Robert W. Baird | Outperform |
| 2025-01-03 | 개시 | William Blair | Outperform |
| 2024-12-16 | 업그레이드 | Stifel | Hold → Buy |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 개시 | B. Riley Securities | Buy |
| 2023-01-30 | 개시 | SVB Securities | Outperform |
| 2022-12-05 | 개시 | Cowen | Outperform |
| 2022-11-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-02 | 개시 | BofA Securities | Buy |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-09-21 | 개시 | Oppenheimer | Outperform |
| 2021-09-01 | 개시 | SMBC Nikko | Outperform |
| 2021-05-18 | 개시 | UBS | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-02-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-02-24 | 개시 | Jefferies | Buy |
| 2020-02-19 | 개시 | Stifel | Hold |
| 2020-01-27 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-26 | 개시 | Wedbush | Neutral |
| 2019-09-13 | 개시 | Nomura | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 개시 | Janney | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 개시 | Goldman | Neutral |
| 2018-01-02 | 개시 | JP Morgan | Overweight |
| 2018-01-02 | 개시 | Morgan Stanley | Overweight |
모두보기
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
Empowered Funds LLC Takes Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Baillie Gifford & Co. Sells 1,031,956 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics (DNLI) to Release Quarterly Earnings on Tuesday - MarketBeat
Mucopolysaccharidosis Market Analysis Across 7MM — Unveiling Growth Opportunities Across Different Types | DelveInsight - GlobeNewswire Inc.
Deutsche Bank sets $31 target for Denali Therapeutics stock - MSN
Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN
(DNLI) On The My Stocks Page - Stock Traders Daily
Denali Therapeutics (NASDAQ:DNLI) Coverage Initiated by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Shares Down 4.9%What's Next? - MarketBeat
abrdn plc Has $8.20 Million Stake in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Deutsche Bank Initiates Coverage of Denali Therapeutics (MUN:4DN) with Buy Recommendation - Nasdaq
Deutsche Bank Initiates Coverage of Denali Therapeutics (DNLI) with Buy Recommendation - Nasdaq
Deutsche Bank sets $31 target for Denali Therapeutics stock By Investing.com - Investing.com Australia
Stifel maintains Buy on Denali Therapeutics, $37 target - MSN
Stifel maintains Buy on Denali Therapeutics, $37 target By Investing.com - Investing.com Australia
Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) Price Target at $38.00 - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 6.2%What's Next? - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Short Interest Up 5.1% in January - MarketBeat
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study - MSN
Denali Therapeutics Announces Primary Analysis and - GlobeNewswire
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - Marketscreener.com
Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa - Marketscreener.com
Where are the Opportunities in (DNLI) - Stock Traders Daily
Leerink Partnrs Has Negative Outlook of DNLI FY2025 Earnings - MarketBeat
Zacks Research Has Bearish Estimate for DNLI FY2024 Earnings - MarketBeat
Denali Gains 26.6% in a Year: How Should You Play the Stock? - MSN
Denali Therapeutics Insiders Sold US$2.2m Of Shares Suggesting Hesitancy - Simply Wall St
What is Leerink Partnrs’ Forecast for DNLI FY2025 Earnings? - Defense World
Zacks Research Has Negative Outlook of DNLI FY2024 Earnings - Defense World
The Goldman Sachs Group Lowers Denali Therapeutics (NASDAQ:DNLI) Price Target to $40.00 - MarketBeat
Alzheimer's Disease Therapeutics Market to Grow by USD 5.41 Billion (2024-2028), Novel Biomarker R&D Boosts Growth, with AI Driving Market TransformationTechnavio - The Malaysian Reserve
Denali Therapeutics Announces Upcoming Presentations on - GlobeNewswire
Revolutionary Brain Barrier Treatment for Hunter Syndrome Takes Center Stage at Major Medical Conference - StockTitan
The Goldman Sachs Group Has Lowered Expectations for Denali Therapeutics (NASDAQ:DNLI) Stock Price - Defense World
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 4.3%Time to Sell? - MarketBeat
How To Trade (DNLI) - Stock Traders Daily
Denali Therapeutics Inc (DNLI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Denali Therapeutics Inc 주식 (DNLI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ho Carole | Chief Medical Officer |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
175,673 |
| Schuth Alexander O. | COFO and Secretary |
Jan 06 '25 |
Sale |
20.22 |
12,255 |
247,796 |
247,215 |
| Schuth Alexander O. | COFO and Secretary |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
244,308 |
| Watts Ryan J. | President and CEO |
Jan 06 '25 |
Sale |
20.22 |
29,266 |
591,759 |
260,721 |
| Watts Ryan J. | President and CEO |
Jan 07 '25 |
Sale |
20.81 |
7,650 |
159,196 |
253,071 |
| Krognes Steve E. | Director |
Jan 07 '25 |
Sale |
20.81 |
3,339 |
69,485 |
25,757 |
0.27%
3.05%
자본화:
|
볼륨(24시간):